NASDAQ:TGTX TG Therapeutics (TGTX) Stock Price, News & Analysis $54.53 +1.23 (+2.31%) Closing price 04:00 PM EasternExtended Trading$54.45 -0.08 (-0.14%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About TG Therapeutics Stock (NASDAQ:TGTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TG Therapeutics alerts:Sign Up Key Stats Today's Range$53.08▼$55.3250-Day Range$47.94▼$58.1152-Week Range$26.76▼$59.30Volume1.06 million shsAverage Volume1.62 million shsMarket Capitalization$8.35 billionP/E Ratio19.90Dividend YieldN/APrice Target$63.00Consensus RatingModerate Buy Company Overview TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system. TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults. BRIUMVI is administered by intravenous infusion and is designed to reduce the number of B cells involved in the disease process. The company previously developed UKONIQ (umbralisib), a treatment for certain types of lymphoma, but voluntarily withdrew the product from the U.S. market in 2022 following discussions with the U.S. Food and Drug Administration concerning safety findings. TG Therapeutics continues to focus on BRIUMVI and its broader pipeline of investigational therapies for immune-mediated and hematologic diseases. Michael S. Weiss serves as the company’s chief executive officer and executive chairman.AI Generated. May Contain Errors. Read More TG Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreTGTX MarketRank™: 3.652110432705 of 5 starsTG Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 205th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingTG Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialTG Therapeutics has a consensus price target of $63.00, representing about 15.5% upside from its current price of $54.53.Amount of Analyst CoverageTG Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TG Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth188.04% Earnings GrowthEarnings for TG Therapeutics are expected to grow by 188.04% in the coming year, from $0.92 to $2.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TG Therapeutics is 19.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.75.Price to Earnings Ratio vs. SectorThe P/E ratio of TG Therapeutics is 19.90, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.02.Price to Earnings Growth RatioTG Therapeutics has a PEG Ratio of 2.28. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTG Therapeutics has a P/B Ratio of 13.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TG Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.96% of the float of TG Therapeutics has been sold short.Short Interest Ratio / Days to CoverTG Therapeutics has a short interest ratio ("days to cover") of 15.03, which indicates bearish sentiment.Change versus previous monthShort interest in TG Therapeutics has recently increased by 1.59%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTG Therapeutics does not currently pay a dividend.Dividend GrowthTG Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentTG Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.Search InterestOnly 9 people have searched for TGTX on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.MarketBeat Follows10 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, TG Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $274,800.00 in company stock.Percentage Held by Insiders8.87% of the stock of TG Therapeutics is held by insiders.Percentage Held by Institutions58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TG Therapeutics' insider trading history. Receive TGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TGTX Stock News HeadlinesTG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple SclerosisOctober 12, 2026 | businesswire.comTg Therapeutics, Inc. Announces Schedule of Data Presentations At Mstoronto2026October 9, 2026 | marketscreener.comMLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.October 20 at 1:00 AM | Profits Run (Ad)TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh NewsflowOctober 9, 2026 | finance.yahoo.comTG Therapeutics (TGTX) Just Sparked A Bigger QuestionOctober 8, 2026 | finance.yahoo.comTG Therapeutics Announces Schedule of Data Presentations at MSToronto2026October 8, 2026 | businesswire.comKuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmSeptember 28, 2026 | prnewswire.comTG Therapeutics Inc (TGTX)September 24, 2026 | ru.investing.comSee More Headlines TGTX Stock Analysis - Frequently Asked Questions How have TGTX shares performed this year? TG Therapeutics' stock was trading at $29.81 at the beginning of the year. Since then, TGTX stock has increased by 82.9% and is now trading at $54.53. How were TG Therapeutics' earnings last quarter? TG Therapeutics, Inc. (NASDAQ:TGTX) issued its earnings results on Monday, August, 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by $0.26. The company's quarterly revenue was up 70.2% on a year-over-year basis. Read the conference call transcript. Who are TG Therapeutics' major shareholders? TG Therapeutics' top institutional shareholders include Congress Asset Management Co. (1.70%), IFP Advisors Inc (0.14%), State of Alaska Department of Revenue (0.03%) and Avaii Wealth Management LLC (0.02%). Insiders that own company stock include Sean A Power, Yann Echelard, Laurence N Charney and Sagar Lonial. View institutional ownership trends. How do I buy shares of TG Therapeutics? Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TG Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TG Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Tesla (TSLA), Intel (INTC), Palantir Technologies (PLTR) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings8/03/2026Today10/20/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TGTX's financial health is in the Green zone, according to TradeSmith. TGTX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TGTX Previous SymbolOTCMKTS:TGTX CIK1001316 Webwww.tgtherapeutics.com Phone(212) 554-4484Fax212-554-4531Employees399Year Founded1993Price Target and Rating Average Price Target for TG Therapeutics$63.00 High Price Target$86.00 Low Price Target$20.00 Potential Upside/Downside+15.5%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$2.74 Trailing P/E Ratio19.90 Forward P/E Ratio59.27 P/E Growth2.28Net Income$447.18 million Net Margins55.22% Pretax Margin12.71% Return on Equity73.49% Return on Assets34.14% Debt Debt-to-Equity Ratio1.23 Current Ratio4.27 Quick Ratio3.72 Sales & Book Value Annual Sales$616.29 million Price / Sales13.54 Cash Flow$2.83 per share Price / Cash Flow19.26 Book Value$4.08 per share Price / Book13.37Miscellaneous Outstanding Shares153,070,000Free Float139,492,000Market Cap$8.35 billion OptionableOptionable Beta1.80 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:TGTX) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
